PASylated interferon alpha - XL-protein GmbH

Drug Profile

PASylated interferon alpha - XL-protein GmbH

Alternative Names: PAS-IFNα; xl-080

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator XL-protein GmbH
  • Class Anti-infectives; Anti-inflammatories; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Infections; Inflammation

Highest Development Phases

  • Preclinical Infections; Inflammation

Most Recent Events

  • 09 Aug 2016 Preclinical trials in Inflammation in Germany (unspecified route)
  • 09 Aug 2016 Preclinical trials in Infections in Germany (unspecified route)
  • 09 Aug 2016 PASylated interferon alpha - XL-protein GmbH is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top